Novo Nordisk A/S (NOVO B)

Novo Nordisk develops pharmaceutical treatments focused on diabetes and obesity, including insulin products and GLP-1 receptor agonists such as Ozempic and Wegovy. The company maintains a leading position in these therapeutic areas through specialized research and extensive manufacturing capacity. It serves patients and healthcare providers in numerous countries worldwide.

Market

Copenhagen

Sector

Healthcare

Trend

Neutral

Last close

298.9 (-0.88% on the day)

MA50

309.31

MA200

291.51

52-week range

220.97–383.09

Market cap

1.3T DKK

P/E

11.27

Dividend yield

3.96%

Data as of

2026-09-04

All markets — KeepWinning global stock screener

Other companies on Copenhagen: Nordea Bank Abp (NDA DK), DSV A/S (DSV), A.P. Møller - Mærsk A/S (MAERSK B), A.P. Møller - Mærsk A/S (MAERSK A), Danske Bank A/S (DANSKE), Novozymes A/S (NSIS B)